Sanofi just put Q3 2026 on the table with a clean headline. Business earnings power looked firm, yet the stock closed at €79.74 on 30 October with only a modest cushion built in after a 30 day return of about 12.6%. The market saw a pharma giant pricing in caution while the report showed Basic EPS of €2.52 and revenue of €15.2b for the quarter. Emotion focused on what comes next. The numbers focused on profitability today.
Like Sanofi’s earnings power but uneasy about how much caution the share price still seems to carry after a 12.6% move? Compare that combination of steady profits and valuation restraint with our 197 high quality undervalued stocks.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): €15,233m vs. €13,170m (up about 15.7%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): €3,021m vs. €2,822m (up about 7.1%)
- Basic EPS (Q3 2026 vs Q3 2025): €2.52 vs. €2.32 (up about 8.7%)
- Pipeline Depth (Q3 2026 vs Q3 2025): 61 vs. 93 late stage and early stage projects across Phase I, Phase II, Phase III and Pre Registration (pipeline mix shifted, with fewer total projects but continued late stage presence)
Sanofi is already lining up Dupixent’s next act. Ask Charlie which new Sanofi drug could replace Dupixent long term.
Sanofi’s Bull Case Hinges On Execution, Not Hope
The bullish view leans heavily on Sanofi’s ability to turn pipeline talk into actual products that protect earnings beyond Dupixent.
"Deep pipeline in immunology, neurology, rare disease and vaccines, with 12 Phase III and 15 Phase II readouts in 2025 and 10 new molecules entering Phase I, positions Sanofi to refresh and broaden its portfolio, which can support revenue and sustain business operating income over time."
Q3 shows progress and friction. On the plus side, specialty launches like ALTUVIIIO and Ayvakit helped drive double digit sales and business EPS growth, and duvakitug’s 44 week Phase 2b IBD data moves a key asset closer to late stage. On the other hand, discontinuation of amlitelimab and itepekimab and €1.031b of impairments underline that pipeline breadth does not automatically translate into durable earnings power.
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.
Sanofi Bear Case: Execution Stumbles Still Visible
The harsher view argues that Sanofi is taking on more science and spending than it can reliably turn into durable profit streams.
"The push to become an R&D driven, AI powered biopharma group, with 12 Phase III and 15 Phase II readouts in 2025 and an expanded early pipeline, increases execution risk and the chance of costly clinical setbacks. This can weigh on future margin progression even as current business EPS growth outpaces sales."
Q3 2026 shows that concern is not theoretical. Management booked €1.031b of impairments tied to amlitelimab and itepekimab discontinuations. Business EPS grew faster than revenue this quarter, yet those write downs highlight that pipeline pruning is already costing real money and keep execution risk a live consideration for Sanofi investors.
Hunt For Quiet Mispricings
Sanofi just showed how a solid profit story can still sit on a cautious share price. The real opportunity is finding companies that could be undervalued before the crowd finishes repricing them.
- Company 1 - 23% below our estimate - sells routers and software that become stickier as customers shift to subscription connectivity for AI heavy devices.
- Company 2 - 21% below our estimate - builds optical modules now filling expanding data center capacity as AI programs demand higher bandwidth links and tighter packaging.
- Company 3 - 38% below our estimate - runs an asset light freight network that tightens carrier vetting using AI to cut fraud and insurance strain.
Those are three of them. See the full list of 197 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com